|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||11.14 - 11.14|
|52-week range||11.14 - 11.14|
|Beta (5Y monthly)||0.86|
|PE ratio (TTM)||N/A|
|Earnings date||08 May 2023 - 12 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...